Doptelet FDA Approval History
Last updated by Judith Stewart, BPharm on July 29, 2025.
FDA Approved: Yes (First approved May 21, 2018)
Brand name: Doptelet
Generic name: avatrombopag
Dosage form: Tablets and Oral Granules
Company: Dova Pharmaceuticals, Inc.
Treatment for: Thrombocytopenia, Immune Thrombocytopenia
Doptelet (avatrombopag) is a second generation, orally administered thrombopoietin receptor agonist (TPO-RA) for use in the treatment of thrombocytopenia.
- Doptelet is indicated for the treatment of:
- Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.
- Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
- Thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. - Doptelet is supplied as Doptelet 20 mg tablets and Doptelet Sprinkle 10 mg capsules containing oral granules.
Development timeline for Doptelet
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.